Position statement

on

genotoxicity / mutagenicity testing of cosmetic ingredients without animal experiments

The SCCP adopted this opinion at its 19th plenary on 21 January 2009
About the Scientific Committees

Three independent non-food Scientific Committees provide the Commission with the scientific advice it needs when preparing policy and proposals relating to consumer safety, public health and the environment. The Committees also draw the Commission's attention to the new or emerging problems which may pose an actual or potential threat.

They are: the Scientific Committee on Consumer Products (SCCP), the Scientific Committee on Health and Environmental Risks (SCHER) and the Scientific Committee on Emerging and Newly Identified Health Risks (SCENIHR) and are made up of external experts.

In addition, the Commission relies upon the work of the European Food Safety Authority (EFSA), the European Medicines Evaluation Agency (EMEA), the European Centre for Disease prevention and Control (ECDC) and the European Chemicals Agency (ECHA).

SCCP

Questions concerning the safety of consumer products (non-food products intended for the consumer).

In particular, the Committee addresses questions related to the safety and allergenic properties of cosmetic products and ingredients with respect to their impact on consumer health, toys, textiles, clothing, personal care products, domestic products such as detergents and consumer services such as tattooing.

Scientific Committee members

Claire Chambers, Gisela Degen, Ruta Dubakiene, Bozena Jazwiec-Kanyion, Vassilios Kapoulas, Jean Krutmann, Carola Lidén, Jean-Paul Marty, Thomas Platzek, Suresh Chandra Rastogi, Jean Revuz, Vera Rogiers, Tore Sanner, Günter Speit, Jacqueline Van Engelen, Ian White

Contact:
European Commission
Health & Consumer Protection DG
Directorate C: Public Health and Risk Assessment
Unit C7 - Risk Assessment
Office: B232 B-1049 Brussels
Sanco-Sc6-Secretariat@ec.europa.eu

© European Commission 2009
(ISSN)

The opinions of the Scientific Committees present the views of the independent scientists who are members of the committees. They do not necessarily reflect the views of the European Commission. The opinions are published by the European Commission in their original language only.

ACKNOWLEDGMENTS

Prof. G. Degen
Dr. B. Jazwiec-Kanyion
Prof. V. Kapoulas
Prof. J.-P. Marty
Prof. T. Platzek
Dr. S.C. Rastogi
Prof. J. Revuz
Prof. V. Rogiers (chairman)
Prof. T. Sanner
Prof. G. Speit (rapporteur)
Dr. J. van Engelen
Dr. I.R. White

Keywords: SCCP, position statement, genotoxicity, mutagenicity, animal testing, alternative methods, 3R, directive 76/768/EEC

Opinion to be cited as: SCCP (Scientific Committee on Consumer Products), position statement on genotoxicity / mutagenicity testing without animal experiments
TABLE OF CONTENTS

ACKNOWLEDGMENTS ........................................................................................................... 3
1. POSITION STATEMENT.......................................................................................... 5
1. POSITION STATEMENT

The Seventh Amendment to the EU Cosmetics Directive 76/768/EEC bans the testing on animals of ingredients or combination of ingredients of cosmetics as of 11 March 2009. Thus, in vivo genotoxicity / mutagenicity tests will no longer be available for this important group of chemicals. At present, in vivo mutagenicity testing plays a crucial role in the evaluation of the mutagenic potential of cosmetic ingredients. According to the current “SCCP Notes of Guidance for the Testing of Cosmetic Ingredients and their Safety Evaluation” (SCCP/1005/06), in vivo tests are required in cases of positive in vitro mutagenicity test results. In vivo tests are not necessary when comprehensive in vitro testing has led to clearly negative results. However, current in vitro test protocols, as defined by international guidelines (e.g., OECD), are designed to identify hazards and to avoid false negative results.

Consequently, negative in vitro test results are highly reliable. In contrast, positive results may be due to experimental conditions that have no relevance for the in vivo situation and thus do not reflect a mutagenic risk of the test compound per se. In order to determine whether a positive in vitro result has any relevance in vivo, follow-up testing in animals is inevitable.

The practical importance of in vivo tests can be illustrated by recent SCCP evaluations of hair dyes (opinions adopted between March 2007 and June 2008). Among the 26 hair dyes evaluated, only two were assessed on the basis of negative in vitro tests only. In vivo tests were performed for 24 out of the 26 hair dyes. These hair dyes showed positive responses in different types of in vitro tests but all led to negative in vivo test results. The following conclusion can be drawn from these data:

1. In vivo testing has a decisive role in current mutagenicity testing since it is not possible to predict the results in vivo based on the outcome of positive in vitro tests alone.

2. The use of an in vitro-only test battery with the currently established in vitro tests for mutagenicity testing might lead to a scientifically unjustified high attrition rate of substances which would have been considered safe after in vivo testing.

In 2007, the SCCP stated in its “Memorandum on Actual Status of Alternative Methods on the Use of Experimental Animals in the Safety Assessment of Cosmetic Ingredients in the European Union” (SCCP/1111/07) that “with the currently available in vitro assays performed in accordance with the actual international guidelines it will not be possible to appropriately evaluate a mutagenic potential in many cases. New in vitro methods and test strategies are needed.” There are several ongoing efforts by international expert groups to define better in vitro test conditions to avoid “irrelevant positives” and to improve existing tests. New in vitro genotoxicity tests (e.g., 3D skin models) are being developed but the process of method development and validation will take some years and the methodology will not be available by March 2009. It is impossible to predict whether these tests can completely substitute in vivo mutagenicity testing. Furthermore it should be noted that in vitro tests do require tissue from treated animals (liver S9-mix).

In summary, the current in vitro tests are very sensitive. In cases where clearly negative results are seen in an appropriate in vitro test battery, a mutagenic potential is excluded. At present no validated replacement methods are available that allow the follow-up of positive
results from standard *in vitro* assays without further animal experiments. Consequently, after 11 March 2009, in many cases, it will not be possible to evaluate the mutagenic potential of cosmetic ingredients on a sound scientific basis. Because the potential mutagenicity of these ingredients is of major concern, an important part of the toxicological evaluation of cosmetic ingredients cannot be accomplished.